Demodex Blepharitis

Ewwww! Gross! Have you seen those things?

Every optometrist addresses ocular surface disease in some capacity and, driven by a growing body of compelling science, many have expanded the range of diagnostic and treatment options they offer as new technologies have emerged.

In this Healio Video Perspective from the virtual AAO annual meeting, Elizabeth Yeu, MD, discusses the current state of blepharitis management, including upcoming clinical trials that could offer a pharmaceutical remedy.

Results from two trials showed that TP-03 was well-tolerated and efficacious in reducing collarettes and Demodex density through 90 days in patients with Demodex blepharitis.

In this Healio Video Perspective, Bobby Azamian, MD, PhD, CEO of Tarsus Pharmaceuticals, discusses TP-03, a topical ophthalmic preparation of an established acaricide, which is now in a phase 2b/3 trial.

In this video, Aziz Mottiwala, newly appointed chief commercial officer for Tarsus Pharmaceuticals, discusses the company’s plans to drive the development of its therapeutic for the treatment of Demodex blepharitis.

Some patients present with specific complaints and describe distinct visual disturbances or irritation, while others are more like an abstract painting awaiting interpretation. Demodex patients are equally represented in both categories.

Results from a phase 2b single-arm, open-label trial that showed use of TP-03 for Demodex blepharitis was safe and well-tolerated after 4 weeks of treatment with persisting effects for at least 90 days.

Ivermectin-metronidazole combined topical gel therapy successfully treated blepharitis caused by Demodex folliculorum infection, according to study results published in Contact Lens and Anterior Eye.

TP-03, a topical ophthalmic preparation of an established acaricide, significantly reduced Demodex density and cylindrical dandruff through 90 days of treatment in a phase 2a pilot study.